The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
Campaign empowers women to prioritise their health through thought provoking films, influencer-led campaigns, scientific and medical podcasts, survivor experiences, and digital awareness
Net profit for the?quarter came in at Rs. 2,889.1 crore, up 4.8 per cent from the year earlier, adjusted for exceptional items
Akums invested Rs. 272 crore in capital expenditure during FY25
The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
Subscribe To Our Newsletter & Stay Updated
